Cipla Shares Surge 4% as Citi Forecasts Growth Catalysts Ahead

Cipla shares witnessed a significant rally on Monday, hitting a high of Rs 1,409 on the BSE after international brokerage firm Citi placed the stock on a "90-day Positive Catalyst Watch." While the company recently faced a dip in quarterly profits, Citi maintains a ‘Buy’ rating with a target price of Rs 1,700, suggesting a potential upside of over 25%.

Key US Market Triggers and Product Launches

The primary driver behind Citi's optimism lies in a series of upcoming developments in the United States market. The brokerage highlighted that the likely approval of gFlovent from Cipla’s Goa facility could significantly bolster growth in the US. Additionally, the expected launch of gVentolin is viewed as a major near-term trigger.

Cipla’s competitive positioning in the US also remains strong, with its Nintedanib product already capturing nearly 50% of the market share. Following a period of recent weakness, Citi expects the US business to undergo a significant revenue rebound. Furthermore, a pending re-inspection of the Indore plant by the USFDA is seen as a critical milestone; a favorable outcome would serve as an additional positive catalyst for the stock.

Robust Domestic Performance and Valuation Edge

While the US market provides growth triggers, Cipla’s India business continues to act as a stable pillar. The domestic segment contributes nearly two-thirds of the company's EBITDA, supported by a healthy recovery in its respiratory portfolio.

From a valuation perspective, Citi argues that Cipla offers more attractive entry points compared to its domestic-focused peers. For instance, Cipla’s India business is valued at 7.8 times FY26 sales, which is more reasonable than Mankind Pharma, which trades at 8.5 times. This provides investors with significant exposure to the growing Indian pharmaceutical market at a more sensible multiple.

The bullish outlook comes despite a challenging Q4 performance. Cipla reported a 55% year-on-year decline in consolidated net profit, falling to Rs 555 crore from Rs 1,222 crore in the same quarter last year. Revenue from operations also saw a marginal dip of 3% to Rs 6,541 crore, while EBITDA margins contracted to 15.2% from 22.8%.

However, Citi believes that earnings have likely "bottomed out" following the impact of gRevlimid. The brokerage also noted that easing geopolitical tensions are helping to stabilize raw material costs, which should support future margins. Currently, the stock trades at 25x FY27E earnings and 21x FY28E earnings, presenting what analysts consider a favorable risk-reward profile.

Key Takeaways

  • Target Upside: Citi maintains a 'Buy' rating for Cipla with a target price of Rs 1,700, implying a 25.55% potential gain.
  • US Growth Drivers: Upcoming catalysts include the potential approval of gFlovent, the launch of gVentolin, and a crucial USFDA re-inspection of the Indore plant.
  • Attractive Valuation: Cipla offers competitive exposure to the Indian market, with its domestic business valued at 7.8x FY26 sales, lower than several key competitors.